vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Hyperscale Data, Inc. (GPUS). Click either name above to swap in a different company.
Hyperscale Data, Inc. is the larger business by last-quarter revenue ($26.9M vs $15.0M, roughly 1.8× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -112.0%, a 113.8% gap on every dollar of revenue. On growth, Hyperscale Data, Inc. posted the faster year-over-year revenue change (38.4% vs 11.5%). CHAMPIONS ONCOLOGY, INC. produced more free cash flow last quarter ($-2.0M vs $-56.2M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -16.3%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Hyperscale Data, Inc. provides GPU-accelerated computing infrastructure and cloud solutions tailored for AI development, big data processing, and high-performance computing workloads. It primarily serves AI startups, large technology firms, and cloud service providers across North America and the Asia-Pacific region, delivering scalable, high-efficiency computing resources to support complex data processing needs.
CSBR vs GPUS — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $26.9M |
| Net Profit | $268.0K | $-30.1M |
| Gross Margin | 51.7% | 14.5% |
| Operating Margin | 1.2% | -117.8% |
| Net Margin | 1.8% | -112.0% |
| Revenue YoY | 11.5% | 38.4% |
| Net Profit YoY | -63.2% | -6670.3% |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $26.9M | ||
| Q3 25 | $14.0M | $24.3M | ||
| Q2 25 | $12.4M | $25.9M | ||
| Q1 25 | $17.0M | $25.0M | ||
| Q4 24 | $13.5M | $19.4M | ||
| Q3 24 | $14.1M | $31.1M | ||
| Q2 24 | $14.0M | $17.8M | ||
| Q1 24 | $12.0M | $38.4M |
| Q4 25 | $268.0K | $-30.1M | ||
| Q3 25 | $-436.0K | $-13.0M | ||
| Q2 25 | $-1.8M | $-19.1M | ||
| Q1 25 | $4.5M | $-4.2M | ||
| Q4 24 | $728.0K | $-445.0K | ||
| Q3 24 | $1.3M | $-25.5M | ||
| Q2 24 | $-109.0K | $-33.9M | ||
| Q1 24 | $-2.5M | $3.7M |
| Q4 25 | 51.7% | 14.5% | ||
| Q3 25 | 42.9% | 25.8% | ||
| Q2 25 | 41.1% | 23.7% | ||
| Q1 25 | 61.2% | 21.1% | ||
| Q4 24 | 44.9% | 6.5% | ||
| Q3 24 | 49.7% | 27.5% | ||
| Q2 24 | 48.2% | -21.3% | ||
| Q1 24 | 34.7% | 47.4% |
| Q4 25 | 1.2% | -117.8% | ||
| Q3 25 | -3.8% | -57.8% | ||
| Q2 25 | -16.2% | -39.2% | ||
| Q1 25 | 26.4% | -25.5% | ||
| Q4 24 | 5.4% | -46.8% | ||
| Q3 24 | 9.5% | -79.2% | ||
| Q2 24 | -1.9% | -151.4% | ||
| Q1 24 | -21.4% | 9.5% |
| Q4 25 | 1.8% | -112.0% | ||
| Q3 25 | -3.1% | -53.5% | ||
| Q2 25 | -14.9% | -73.7% | ||
| Q1 25 | 26.4% | -16.8% | ||
| Q4 24 | 5.4% | -2.3% | ||
| Q3 24 | 9.3% | -82.3% | ||
| Q2 24 | -0.8% | -190.7% | ||
| Q1 24 | -21.1% | 9.7% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $-0.03 | $-0.39 | ||
| Q2 25 | $-0.12 | $-2.66 | ||
| Q1 25 | $0.31 | — | ||
| Q4 24 | $0.05 | $-8.78 | ||
| Q3 24 | $0.09 | $-24.82 | ||
| Q2 24 | $-0.01 | $-37.81 | ||
| Q1 24 | $-0.19 | $3.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $13.1M |
| Total DebtLower is stronger | — | $83.1M |
| Stockholders' EquityBook value | $4.2M | $119.8M |
| Total Assets | $30.2M | $313.7M |
| Debt / EquityLower = less leverage | — | 0.69× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $13.1M | ||
| Q3 25 | $10.3M | $24.8M | ||
| Q2 25 | $9.8M | $5.9M | ||
| Q1 25 | $3.2M | $4.2M | ||
| Q4 24 | $2.8M | $4.5M | ||
| Q3 24 | $2.9M | $7.9M | ||
| Q2 24 | $2.6M | $9.6M | ||
| Q1 24 | $4.5M | $18.9M |
| Q4 25 | — | $83.1M | ||
| Q3 25 | — | $80.0M | ||
| Q2 25 | — | $88.5M | ||
| Q1 25 | — | $92.8M | ||
| Q4 24 | — | $96.7M | ||
| Q3 24 | — | $104.8M | ||
| Q2 24 | — | $106.8M | ||
| Q1 24 | — | $30.0M |
| Q4 25 | $4.2M | $119.8M | ||
| Q3 25 | $3.5M | $55.9M | ||
| Q2 25 | $3.8M | $5.5M | ||
| Q1 25 | $5.5M | $6.3M | ||
| Q4 24 | $681.0K | $8.6M | ||
| Q3 24 | $-332.0K | $2.7M | ||
| Q2 24 | $-1.9M | $26.7M | ||
| Q1 24 | $-2.1M | $59.0M |
| Q4 25 | $30.2M | $313.7M | ||
| Q3 25 | $30.5M | $242.4M | ||
| Q2 25 | $32.3M | $213.5M | ||
| Q1 25 | $30.6M | $218.5M | ||
| Q4 24 | $25.2M | $220.8M | ||
| Q3 24 | $24.9M | $231.5M | ||
| Q2 24 | $26.1M | $270.8M | ||
| Q1 24 | $26.8M | $299.8M |
| Q4 25 | — | 0.69× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 16.06× | ||
| Q1 25 | — | 14.71× | ||
| Q4 24 | — | 11.19× | ||
| Q3 24 | — | 38.41× | ||
| Q2 24 | — | 4.00× | ||
| Q1 24 | — | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-37.7M |
| Free Cash FlowOCF − Capex | $-2.0M | $-56.2M |
| FCF MarginFCF / Revenue | -13.1% | -208.7% |
| Capex IntensityCapex / Revenue | 1.6% | 68.6% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-87.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-37.7M | ||
| Q3 25 | $600.0K | $-17.8M | ||
| Q2 25 | $6.9M | $-3.1M | ||
| Q1 25 | $490.0K | $-4.0M | ||
| Q4 24 | $-283.0K | $-9.2M | ||
| Q3 24 | $311.0K | $3.7M | ||
| Q2 24 | $-1.8M | $-3.7M | ||
| Q1 24 | $-919.0K | $-10.2M |
| Q4 25 | $-2.0M | $-56.2M | ||
| Q3 25 | $554.0K | $-20.6M | ||
| Q2 25 | $6.6M | $-3.5M | ||
| Q1 25 | $448.0K | $-6.8M | ||
| Q4 24 | $-377.0K | $-9.3M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | $-1.8M | $-5.9M | ||
| Q1 24 | $-1.0M | $-11.6M |
| Q4 25 | -13.1% | -208.7% | ||
| Q3 25 | 4.0% | -84.5% | ||
| Q2 25 | 53.5% | -13.5% | ||
| Q1 25 | 2.6% | -27.3% | ||
| Q4 24 | -2.8% | -47.6% | ||
| Q3 24 | — | 8.4% | ||
| Q2 24 | -13.0% | -33.4% | ||
| Q1 24 | -8.4% | -30.3% |
| Q4 25 | 1.6% | 68.6% | ||
| Q3 25 | 0.3% | 11.5% | ||
| Q2 25 | 2.0% | 1.5% | ||
| Q1 25 | 0.2% | 11.5% | ||
| Q4 24 | 0.7% | 0.3% | ||
| Q3 24 | 0.0% | 3.6% | ||
| Q2 24 | 0.0% | 12.6% | ||
| Q1 24 | 0.8% | 3.7% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -2.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
GPUS
| Transferred Over Time | $10.4M | 39% |
| Revenue From Mined Crypto Assets At Sentinum Owned And Operated Facilities | $5.8M | 21% |
| Hotel And Real Estate Operations | $4.8M | 18% |
| Other | $4.0M | 15% |
| Turn On Green | $2.0M | 7% |
